^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PM54

    i
    Other names: PM54, PM 54, PM-54
    Associations

    News

    Trials
    Company:
    PharmaMar
    Drug class:
    Transcription inhibitor
    Associations

    News

    Trials
    3ms
    Clinical Trial of PM54 in Advanced Solid Tumors Patients. (clinicaltrials.gov)
    P1, N=125, Recruiting, PharmaMar | Trial completion date: Mar 2026 --> Apr 2027 | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    HER-2 positive • HR positive • BRAF mutation • BRAF wild-type
    |
    PM54
    12ms
    Ecteinascidin synthetic analogues: a new class of selective inhibitors of transcription, exerting immunogenic cell death in refractory malignant pleural mesothelioma. (PubMed, J Exp Clin Cancer Res)
    Collectively, these findings reveal a previously unknown mechanism of action of ecteinascidins that merits further investigation for potential clinical applications in the treatment of MPM, as new first line treatment in monotherapy or in association with immunotherapy.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    Tecentriq (atezolizumab) • pemetrexed • Zepzelca (lurbinectedin) • PM54 • ecubectedin (PM14)
    over2years
    Clinical Trial of PM54 in Advanced Solid Tumors Patients. (clinicaltrials.gov)
    P1, N=125, Recruiting, PharmaMar
    New P1 trial
    |
    BRAF (B-raf proto-oncogene) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    HER-2 positive • BRCA2 mutation • BRCA1 mutation • HR positive • BRAF mutation • BRAF wild-type
    |
    PM54